Amended Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ)
LUND, Sweden, Nov. 30, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced an increase of the number of shares and votes in NeuroVive of 1,760,000 as a result of a directed share issue in NeuroVive Pharmaceuti...
NeuroVive's Genetic Mitochondrial Disease Program NVP015 Reaches Significant Milestone
LUND, Sweden, Nov. 30, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that molecules in its NVP015 program have demonstrated positive effects in experimental models of genetic mitochondrial disease and th...
NeuroVive Presents TBI Clinical Study Results at Nordic Neurotrauma Conference
LUND, Sweden, Nov. 15, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company will present data from its clinical phase IIa study on traumatic brain injury (TBI), Copenhagen Head Injury Ciclosporin Study (CHIC), at the Nordic Neurot...
NeuroVive Signs Collaboration Agreement With University of Florida for TBI Biomarker Development
LUND, Sweden, Oct. 31, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has signed a collaboration agreement withKevin K.W. Wang, Ph.D., of the University of Florida to conduct biomarker research for NeuroVive's traumatic brai...
NeuroVive and Lund University Collaboration Receives Grant for Liver Cancer Research
LUND, Sweden, Oct. 18, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that NeuroVive andRamin Massoumi at Lund University have been granted 2.5 MSEK from the Swedish Foundation for Strategic Research (SFF...
NeuroVive's Collaborator, the Children's Hospital of Philadelphia Awarded NIH Grant to Study NVP015 Against Chemical Threats
LUND, Sweden, Oct. 6, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (NASDAQ Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that its research collaboration partner the Children's Hospital ofPhiladelphia (CHOP) has received a two-year grant, #1R21NS103826-01f ...
NeuroVive Receives Research Grant From Vinnova for Development of the NVP015 Genetic Mitochondrial Disease Project
LUND, Sweden, June 1, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company receives close to 1 million SEK in a research grant from Swedish innovation agency, Vinnova, for developing a new treatment for genetic mitochondrial diseas...
NeuroVive Pharmaceutical AB Interim Report January - March 2017
STOCKHOLM, May 18, 2017 /PRNewswire/ -- Broadened project portfolio Business operations Significant events January-March 2017 * Strong inhibitory effects demonstrated in human hepatocellular carcinoma cells and in an experimental model of liver cancer with the Company's new generation of s...
NeuroVive in-licenses a Genetic Mitochondrial Disease Clinical Stage Project From Yungjin Pharm
LUND, Sweden and SEOUL, South Korea, May 2, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today jointly announced that they have entered into a global licensing agreement on Yungjin P...
NeuroVive Presents Preclinical Findings of NV556 in NASH Showing Confirmatory Anti-fibrotic Effects
LUND, Sweden, April 20, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) ("NeuroVive")today announced positive preclinical results demonstrating anti-fibrotic effects with NV556, the company's preclinical compound for non-alcoholic steatohepatitis (NASH), in ...
